Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer

Journal of Clinical Oncology

Volumn 27, Issue 12, 2009, Pages 1976-1982

  Khuri, Fadlo R ^b   Holsinger, F Christopher ^a   Kies, Merrill S ^a   Diaz Jr , Eduardo M ^a   Gillenwater, Ann M ^a   Lewin, Jan S ^a   Ginsberg, Lawrence E ^a   Glisson, Bonnie S ^a   Garden, Adam S ^b   Ark, Nebil ^a   Lin, Heather Y ^a   Lee, J Jack ^a   El Naggar, Adel K ^a   Hong, Waun Ki ^a   Shin, Dong M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; PACLITAXEL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSERVATIONAL LARYNX SURGERY; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHAGIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HEARING DISORDER; HEARING IMPAIRMENT; HISTOLOGY; HUMAN; LARYNX CANCER; LARYNX SURGERY; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; ORGAN PRESERVATION; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH TUBE; THROMBOCYTOPENIA; TRACHEOTOMY; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; LARYNGEAL NEOPLASMS; LARYNGECTOMY; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65349124781     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.6396     Document Type: Article

References (30)

1. Mendenhall WM, Werning JW, Hinerman RW, et al: Management of T1-T2 glottic carcinomas. Cancer 100:1786-1792, 2004
2. Viani L, Stell PM, Dalby JE: Recurrence after radiotherapy for glottic carcinoma. Cancer 67:577- 584, 1991
3. Holsinger FC, Funk E, Roberts DB, et al: Conservation laryngeal surgery versus total laryngectomy for radiation failure in laryngeal cancer. Head Neck 28:779-784, 2006
4. The Department of Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685-1690, 1991
5. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098, 2003
6. Forastiere AA, Maor M, Weber RS, et al: Long-term results of Intergroup RTOG 91-11: A phase III trial to preserve the larynx-Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol 24:284s, 2006 (suppl; abstr 5517)
7. Logemann JA, Rademaker AW, Pauloski BR, et al: Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck 28:64-73, 2006
8. Logemann JA, Pauloski BR, Rademaker AW, et al: Swallowing disorders in the first year after radiation and chemoradiation. Head Neck 30:148- 158, 2008
9. Hutcheson KA, Barringer DA, Rosenthal DI, et al: Swallowing outcomes after radiotherapy for laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 134:178-183, 2008
10. Weber RS, Berkey BA, Forastiere A, et al: Outcome of salvage total laryngectomy following organ preservation therapy: The Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg 129:44-49, 2003
11. Holsinger FC, Weber RS: Swing of the surgical pendulum: A return to surgery for treatment of head and neck cancer in the 21st century? Int J Radiat Oncol Biol Phys 69:S129-S131, 2007
12. Laccourreye O, Brasnu D, Bassot V, et al: Cisplatin-fluorouracil exclusive chemotherapy for T1- T3N0 glottic squamous cell carcinoma complete clinical responders: Five-year results. J Clin Oncol 14:2331-2336, 1996
13. Laccourreye O, Diaz EM Jr, Bassot V, et al: A multimodal strategy for the treatment of patients with T2 invasive squamous cell carcinoma of the glottis. Cancer 85:40-46, 1999
14. Laccourreye O, Veivers D, Hans S, et al: Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders. Cancer 92:1504-1511, 2001
15. Shin DM, Glisson BS, Khuri FR, et al: Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 16:1325-1330, 1998
16. Shin DM, Khuri FR, Glisson BS, et al: Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 91:1316-1323, 2001
17. Shin DM, Glisson BS, Khuri FR, et al: Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 95:322-330, 2002
18. Pfister DG, Laurie SA, Weinstein GS, et al: American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 24:3693-3704, 2006
19. Woolson RF, Clarke WR: Statistical Methods for the Analysis of Biomedical Data (ed 2). New York, NY, Wiley, 2002
20. Hinerman RW, Mendenhall WM, Amdur RJ, et al: Carcinoma of the supraglottic larynx: Treatment results with radiotherapy alone or with planned neck dissection. Head Neck 24:456-467, 2002
21. Frata P, Cellai E, Magrini SM, et al: Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2N0 disease. Int J Radiat Oncol Biol Phys 63:1387-1394, 2005
22. Machtay M, Moughan J, Trotti A, et al: Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. J Clin Oncol 26:3582-3589, 2008
23. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al: Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23:8636-8645, 2005
24. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705- 1715, 2007
25. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695- 1704, 2007
26. Colevas AD, Busse PM, Norris CM, et al: Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A phase I/II trial. J Clin Oncol 16:1331-1339, 1998
27. Posner MR, Glisson B, Frenette G, et al: Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 19:1096-1104, 2001
28. Holsinger FC: Swing of the pendulum: Optimizing functional outcomes in larynx cancer. Curr Oncol Rep 10:170-175, 2008
29. Potti A, Mukherjee S, Petersen R, et al: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355:570- 580, 2006
30. Varmus H: The new era in cancer research. Science 312:1162-1165, 2006